Pharmacotherapy of specific and unspecific respiratory infections
| Autor: | Ivan Fedorin, Ya. M. Balabanova, R. Koker, S. I. Kuznetsov, M. Raddy, Rifat Atun, K. Grem, A. V. Zhestkov, F. Drobnevsky, N. N. Kryukov |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty genetic structures Acute Tonsillitis business.industry Drug resistance medicine.disease behavioral disciplines and activities Pneumonia Pharmacotherapy nervous system Internal medicine medicine Bronchitis Dosing Adverse effect business psychological phenomena and processes Rifampicin medicine.drug |
| Zdroj: | PULMONOLOGIYA. :87-92 |
| ISSN: | 2541-9617 0869-0189 |
| DOI: | 10.18093/0869-0189-2005-0-1-87-92 |
| Popis: | Irrational administration of antimicrobials, incorrect regimens and dosing provide occurrence of adverse effects with minimal therapeutic results and development of drug resistance including anti-tuberculosis drugs. The study was designed to detect information sources on drug therapy used by general practitioners and TB specialists, to establish stereotypical models of antibacterial drug administration in prevalent upper and lower airway diseases at the Samara region and to substantiate the supposition about unreasonable empiric administration of anti-tuberculosis drugs in a respiratory patient without microbiological confirmation as a probable cause of drug resistant tuberculosis. A cross-sectional study based on a special questionnaire was performed in 425 general practitioners in primary care facilities, hospitals and in TB specialists at the Samara region. The questionnaire contained several clinical situations and their solving and the respondents should choose the most suitable ones. Results demonstrated that majority of the practitioners (80 %, or 340 / 425 cases) widely use advertising information regarding antimicrobials. Several doctors (1.7 %) chose antibacterial drugs to treat acute respiratory viral infection, 0.8 to 1.6 % of doctors certainly decided to administer anti-tuberculotics in non-TB respiratory diseases such as acute bronchitis, chronic obstructive pulmonary disease, communityacquired pneumonia and acute tonsillitis, and approximately one fifth of the practitioners thought to administer antituberculotics in these diseases (18.4 % (78 / 425) – rifampicin, 21.2 % (90 / 425) – isoniasid). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|